Paris, France [26 July], 2022 -- Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialization company, today announces the enrolment of the first five ...
Orphalan announces FDA approval of Cuvrior for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine Paris, France 2May2022 - Orphalan SA ...
Paris, France, April 20, 2023 – Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialization company, today announces the commercial launch in the US of ...
PARIS, Dec. 12, 2025 /PRNewswire/ -- Orphalan, an international pharmaceutical company specializing in the development and commercialization of orphan drugs, has acquired Orphelia Pharma, a company ...
(MENAFN- GlobeNewsWire - Nasdaq) Orphalan announces China NMPA's approval of its trientine tetrahydrochloride product for the treatment of Wilson disease Paris, France 18 January , 2024 - Orphalan SA ...
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry ("iWDRegistry") World's first global Wilson's Registry will provide an international ...
World's first global Wilson's Registry will provide an international platform for sharing real-world information about Wilson's disease Registry expected to include 500 individuals affected by this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results